1369665-02-0 Usage
Uses
Used in Pharmaceutical Industry:
Cobimetinib Fumarate is used as an anticancer agent for the treatment of patients with unresectable or metastatic melanoma. It is particularly effective when used in combination with vemurafenib, another MAPK inhibitor, to target the MAPK signaling pathway and inhibit the growth and proliferation of cancer cells.
Used in Oncology Research:
Cobimetinib Fumarate is also used as a research tool in the field of oncology. It helps researchers understand the role of the MAPK signaling pathway in cancer development and progression, as well as the potential of targeting this pathway for therapeutic intervention. This knowledge can lead to the development of new and more effective cancer treatments.
Used in Drug Combination Therapy:
Cobimetinib Fumarate is used as a component in drug combination therapy for the treatment of melanoma. When combined with vemurafenib, it can enhance the therapeutic effects and overcome resistance to single-agent treatments, providing a more effective treatment option for patients with unresectable or metastatic melanoma.
Check Digit Verification of cas no
The CAS Registry Mumber 1369665-02-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,9,6,6 and 5 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1369665-02:
(9*1)+(8*3)+(7*6)+(6*9)+(5*6)+(4*6)+(3*5)+(2*0)+(1*2)=200
200 % 10 = 0
So 1369665-02-0 is a valid CAS Registry Number.
1369665-02-0Relevant articles and documents
PROCESS FOR THE PRODUCTION OF COBIMETINIB
-
, (2019/05/22)
The present invention relates to a novel route of synthesis for the production of enantiomerically pure Cobimetinib, new intermediates in the synthesis of Cobimetinib and an amorphous Cobimetinib hemifumarate salt comprising a high salt content.
CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL] [3-HYDROXY-3-(PIPERIDIN-2-YL) AZETIDIN-1-YL]-METHANONE
-
, (2017/01/26)
This disclosure relates to the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-l-yl]-methanone. The disclosure also relates to pharmaceutical compositions comprising the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-l-yl]-methanone. The disclosure also relates to methods of treating cancers comprising administering to a patient in need thereof the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone.
